PC-1005 gel / National Institute of Allergy and Infectious Diseases - LARVOL DELTA

Phase I Dose Volume Escalation of Rectally Administered PC-1005 to Assess Safety, Pharmacokinetics, and Antiviral Pharmacodynamics as a Multipurpose Prevention Technology (MTN-037). (PubMed, J Acquir Immune Defic Syndr) - P1 | "MIV-150 rectal tissue concentrations were below the 100 ng/g target concentration and transient. Ex vivo assays demonstrated antiviral HSV and HPV effects but not against HIV. PC-1005 requires a more potent antiviral and longer-lasting formulation for further consideration as a multipurpose prevention technology candidate."

Journal • P1 data • PK/PD data • Herpes Simplex • Human Immunodeficiency Virus • Infectious Disease • Oncology

PC1005 Mobilize for action on sexually transmitted infections Session 5: Increasing political commitment: Building support and investment for STIs (AIDS 2024) - "This fundamental element for the effective control of STIs necessitates adequate funding, multisectoral policies, and dedicated programmes. This closing session will also share key insights on the way forward towards 2030 and highlight key STI-related sessions at AIDS 2024."

Human Immunodeficiency Virus • Infectious Disease

Safety of carrageenan-based gels as preventive microbicides: a narrative review. (PubMed, Sex Transm Infect) - "Carrageenan-based gels are generally well tolerated for vaginal and penile, but not anal use. Studies on carrageenan gel's safety for anal use are scarce."

Journal • Review • Infectious Disease • Oncology

Acceptability of PC-1005 Gel Administered Rectally to HIV-1 Seronegative Adults at Three Different Volume Levels (MTN-037). (PubMed, AIDS Educ Prev) - "Participants rated overall gel acceptability on a scale of 1-10, with a median of 7.17 (SD = 2.04) and had positive feelings about all three dose volumes, citing them to be very comfortable or comfortable (dose 1 = 91.7%; dose 2 = 91.7%; dose 3 = 83.3%). High acceptability of and comfort with all three dose volumes shows promise for PC-1005 as an MPT to prevent HIV and STIs, warranting future clinical development."

Journal • Human Immunodeficiency Virus • Infectious Disease

Magnesium lignosulfonate-derived N, S co-doped 3D flower-like hierarchically porous carbon as an advanced metal-free electrocatalyst towards oxygen reduction reaction. (PubMed, Int J Biol Macromol) - "When the ratio of MgO to ZnCl is 10:0.5, NSLPC-1005 possesses the highest ORR activity with an enormous surface area (1752.54 m g), abundant active sites, and a hierarchical porous network structure...It exhibits attractive ORR performance as well as outstanding cyclic stability that are comparable to commercial Pt/C electrocatalysts. This research developed an effective approach to synthesize metal-free carbon materials with high activity and long-term durability as electrocatalysts, which have a promising application in sustainable energy conversion technology."

Journal

[VIRTUAL] Anti-HPV and anti-HSV activity in rectal enema effluents collected from subjects receiving PC-1005: a dual compartment multipurpose prevention technology formulation (HIVR4P 2021) - "Our results support the further evaluation of PC-1005 as an on-demand formulation to prevent HPV and HSV infections."

Clinical • Late-breaking abstract • Herpes Simplex • Human Immunodeficiency Virus • Infectious Disease • Oncology

[VIRTUAL] Phase 1 safety and pharmacokinetic study of candidate rectal microbicide PC-1005 rectal gel (MIV-150/zinc acetate /carrageenan) in HIV-1 seronegative adults (MTN-037) (HIVR4P 2021) - "PC-1005 gel was well-tolerated with low systemic exposure. MIV-150 rectal tissue concentrations were transient and below the 100 ng/g target; no MIV-150 was detectable in vaginal fluids. Based on concentration data, a longer-acting reformulation delivering more MIV-150 to rectal tissues is likely needed to support further development of PC-1005 as an on demand HIV rectal microbicide."

Clinical • P1 data • PK/PD data • Human Immunodeficiency Virus • Infectious Disease